Covestor’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Covestor’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-188	Closed	-$11K	–	2912
2023 Q4	$11K	Sell	188 -1	-0.5%	-$56	0.01%	1530
2023 Q3	$8K	Sell	189 -1	-0.5%	-$36	0.01%	1596
2023 Q2	$7K	Sell	190 -1	-0.5%	-$41	0.01%	1658
2023 Q1	$7K	Buy	191 +35	+22%	+$1.57K	0.01%	1496
2022 Q4	$7K	Buy	156 +153	+5,100%	+$9.9K	0.01%	1497
2022 Q3	$0	Buy	+3	New	+$222	﹤0.01%	2783
2022 Q2	–	Sell	-1	Closed	-$64	–	2494
2022 Q1	$0	Hold	1	–	–	﹤0.01%	2524
2021 Q4	$0	Buy	+1	New	+$155	﹤0.01%	2345

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Covestor's MRTX Position: Q1 2024 in Review

Covestor sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 188 shares — an estimated $11K sold.

Covestor first reported a position in MRTX in Q4 2021 and held it in 8 quarters. The position peaked at $11K in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Covestor reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Covestor sold 188 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $11K.
Covestor first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
Covestor's Mirati Therapeutics, Inc. Common Stock position peaked at $11K in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Covestor's 13F filing for Q1 2024, filed 10 May 2024.